Brief: Hls Therapeutics Q1 Loss Per Share $0.14
09/05/2019 11:58
HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS ANNOUNCES Q1 2019 FINANCIAL RESULTS
* Q1 REVENUE OF $13.2 MILLION, ADJUSTED EBITDA OF $8.3
MILLION AND
CASH FROM OPERATIONS OF $8.3 MILLION
* Q1 LOSS PER SHARE $0.14
* AS AT MARCH 31, 2019, COMPANY HAD CASH AND CASH
EQUIVALENTS OF
$12.8 MILLION, UP FROM $10.9 MILLION AT DECEMBER 31, 2018.
Source text for Eikon: ID:nCNW1Tkrha
Further company coverage: HLS.TO
Recent news on HLS Therapeutics
See all newsCanada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease